Limitations on Development. After the Signing Date and during the Term, neither Party nor any of its Affiliates shall, directly or through any Third Party, sponsor, conduct or cause to be conducted, otherwise assist in, or supply any Collaboration Product for use in connection with, or otherwise fund, any Clinical Trial of any Collaboration Product outside of the Development Plan, without the prior written consent of the other Party.
Limitations on Development. Except as specifically provided herein, all activities of the parties outside of this Agreement are outside of the scope of this Agreement, and nothing herein is intended to limit Genetronics or its Affiliates from using the Genetronics Technology and any Joint Patent Rights or Ethicon or its Affiliates from using any Joint Patent Rights for other purposes.
Limitations on Development. Neither Borrower, Guarantor nor any Affiliate of Borrower or Guarantor shall develop any other Business locations (signing a lease agreement or franchise agreement or acquiring the property on which a Business will be located) without Lender’s consent, if:
(i) any Event of Default has occurred and is continuing;
Limitations on Development. (i) Except as expressly approved in advance in writing by the Parties, neither Servier, nor any of its Affiliates or sublicensees shall, directly or through any Third Party, sponsor, conduct or cause to be conducted, otherwise assist in, supply any Licensed Antibody or Product for use in connection with, fund or otherwise support any human clinical trial (including without limitation any investigator sponsored studies) using such Licensed Antibody or Product for any indication or use in the Remaining Field, in the Retained Territory.
(ii) Except as expressly approved in advance in writing by the Parties, neither XOMA, nor any of its Affiliates, licensees or sublicensees shall, directly or through any Third Party, sponsor, conduct or cause to be conducted, otherwise assist in, supply any Licensed Antibody or Product for use in connection with, fund or otherwise support any human clinical trial (including without limitation any investigator sponsored studies) using such Licensed Antibody or Product for any indication or use in the Cardiometabolic Field, in the Retained Territory.
Limitations on Development. During the Term, except as expressly approved in advance in writing by the other Party, neither Party nor any of its Affiliates shall, directly or through any Third Party, sponsor, conduct or cause to be conducted, otherwise assist in, supply any Licensed Compound or Licensed Product for use in connection with, fund or otherwise support any preclinical studies, non-clinical studies or Clinical Study (including without limitation, any Investigator-Sponsored Trial) using such Licensed Compound or Licensed Product for any Retained Indication in the Territory.
Limitations on Development. After the Original Effective Date and during the term of this Agreement, neither BMS nor EXEL nor any of its Affiliates shall, directly or through any Third Party, sponsor, conduct or cause to be conducted, otherwise assist in, supply any Product for use in connection with, or otherwise fund, any clinical trial or clinical study of any Product outside of the Global Development Plan or any Annual Development Plan, without the prior written consent of such other Party.
Limitations on Development. During the Term, except as expressly approved in advance in writing by the other Party, neither Party nor any of its Affiliates shall, directly or through any Third Party, sponsor, conduct or cause to be conducted, otherwise assist in,
Limitations on Development. No portion of the Property may be developed prior to the City’s final approval of a Site Plan Review and Conditional Use Permit to construct a public elementary school on the Property. In the event the District cannot obtain Site Plan Review and Conditional Use Permit approval for an elementary school within two years of the execution of this Agreement, or if the agreement between the District and the Owner to convey the Property is terminated before the conveyance, the parties will cooperate to effectuate a withdrawal the Property from the City limits pursuant to ORS 222.460. The District will bear all costs for the withdrawal. The District and the Owner agree not to object to such withdrawal, and, in the event of withdrawal, this Agreement will terminate. If the agreement between the District and the Owner to convey the property is terminated, the District and the Owner will jointly provide notice of the termination to the City.
Limitations on Development. (a) During the Term, except as described in Section 6.4, as set forth in the Licensed Field Development Plan or as expressly approved in advance in writing by BMS, neither Alder nor any of its Affiliates shall, directly or through any Third Party, sponsor, conduct or cause to be conducted, otherwise assist in, supply any Licensed Compound or Cancer Product for use in connection with, fund or otherwise support any Clinical Trial (including without limitation any investigator sponsored studies) using such Licensed Compound or Cancer Product outside of the Cancer Field.
(b) During the Term, except as expressly approved in advance in writing by Alder and except in the case where BMS has exercised the Option, neither BMS nor any of its Affiliates shall, directly or through any Third Party, sponsor, conduct or cause to be conducted, otherwise assist in, supply any Licensed Compound or Licensed Product for use in connection with, fund or otherwise support any Clinical Trial (including without limitation any investigator sponsored studies) using such Licensed Compound or Licensed Product in the Cancer Field or outside the Licensed Field.
Limitations on Development. Upon annexation Owners agree that no portion of the Property may be developed prior to the City's final approval of the Petrosa Master Plan. Development of the Property under the Petrosa Master Plan will be subject to additional land use and permit approval as provided in the BDC.
